Effect of inferior caval valve implantation on circulating immune cells and inflammatory mediators in severe tricuspid regurgitation

期刊论文
出版模式：

开放获取
发表日期：

2024年7月18日

查看全文

Isabel Mattig,
Bernd Hewing,
Fabian Knebel,
Christian Meisel,
Antje Ludwig,
Frank Konietschke,
Verena Stangl,
Karl Stangl,
Michael Laule,
Henryk Dreger

摘要

Background

Interventional valve implantation into the inferior vena cava (CAVI) lowers venous congestion in patients with tricuspid regurgitation (TR). We evaluated the impact of a reduction of abdominal venous congestion following CAVI on circulating immune cells and inflammatory mediators.

Methods

Patients with severe TR were randomized to optimal medical therapy (OMT) + CAVI (n = 8) or OMT (n = 10). In the OMT + CAVI group, an Edwards Sapien XT valve was implanted into the inferior vena cava. Immune cells and inflammatory mediators were measured in the peripheral blood at baseline and three-month follow-up.

Results

Leukocytes, monocytes, basophils, eosinophils, neutrophils, lymphocytes, B, T and natural killer cells and inflammatory markers (C-reactive protein, interferon-gamma, interleukin-2, -4, -5, -10, and tumor necrosis factor-alpha) did not change substantially between baseline and three-month follow-up within the OMT + CAVI and OMT group.

Conclusion

The present data suggest that reduction of venous congestion following OMT + CAVI may not lead to substantial changes in systemic inflammation within a short-term follow-up.

Clinical trial registration

NCT02387697

Graphical Abstract